Engineered bone marrow system, methods, devices and uses thereof

The engineered bone marrow platform with 3D microenvironments and multiplex stable-isotope labeling addresses the limitations of 2D systems by providing comprehensive insights into leukemia-niche interactions and drug resistance, facilitating precision drug screening and therapy guidance.

WO2026235565A1PCT designated stage Publication Date: 2026-11-12MYCANCER - TECHNOLOGY FOR FUNCTIONAL PRECISION ONCOLOGY LDA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/PT2026/050018
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current 2D culture systems fail to recapitulate the spatial organization, mechanical properties, and vascular networks of human bone marrow niches, limiting the understanding of leukemia-niche interactions and drug resistance mechanisms, and lack the ability to quantitatively resolve signaling exchanges between niche components and leukemia cells, particularly under flow and chemotherapy exposure.

Method used

A humanized engineered bone marrow platform with interacting 3D microenvironments mimicking endosteal-like and vascular-like niches, integrated within a microfluidic device, utilizing a porous scaffold and hydrogel for controlled perfusion and dynamic infusion, combined with multiplex stable-isotope labeling for compartment-resolved mapping of signaling networks.

Benefits of technology

Enables compartment-resolved recovery and analysis of signaling networks, identifying pathways associated with leukemia homing, niche remodeling, stress response, and drug resistance, supporting precision drug screening and therapy guidance, and predicting minimal residual disease and relapse risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000029_0000
    Figure 00000029_0000
  • Figure 00000030_0000
    Figure 00000030_0000
  • Figure 00000031_0000
    Figure 00000031_0000
Patent Text Reader

Abstract

Herein disclosed is an engineered human bone-marrow-on-chip platform and multiplex proteomic methods for mapping leukemia– niche signaling and drug resistance. The platform comprises interacting 3D microenvironments mimicking endosteal-like and vascular-like bone marrow niches, optionally integrated within a multi-compartment microfluidic device configured for perfusion and dynamic infusion of leukemia cells and drugs. In preferred embodiments, a porous bone-mimetic scaffold forms the endosteal- like niche and a hydrogel supports spontaneous formation of interconnected vascular networks forming the vascular-like niche. Distinct niche and leukemia cell populations are pre-labeled with different stable-isotope amino acids (e.g., 4-plex SILAC) prior to assembly and co-culture. After leukemia exposure and / or chemotherapy treatment, compartment-resolved recovery of endosteal-attached cells, vascular-located cells, circulating leukemia blasts and secretome enables quantitative mass spectrometry to reconstruct directional signaling networks and identify pathways associated with niche remodeling, stress responses, dormancy and drug resistance. The invention further provides methods, devices and kits for precision drug screening, biomarker discovery and therapy guidance related to minimal residual disease and relapse.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] ENGINEERED BONE MARROW SYSTEM, METHODS, DEVICES AND USES THEREOF

[0003] Technical field of the invention

[0004] The present disclosure relates to microphysiological systems, organ-on-chip platforms and quantitative proteomics. In particular, it relates to engineered human bone marrow niche constructs integrated into microfluidic devices and to multiplex stable-isotope labeling approaches for compartment-resolved mapping of signaling networks during leukemia progression and chemotherapy exposure. The disclosure further relates to methods, devices, kits and uses thereof for drug screening, precision medicine and minimal residual disease (MRD) guidance.

[0005] State of the art

[0006] Acute myeloid leukemia (AML) progression and relapse are strongly influenced by bone marrow (BM) niches. In vivo studies indicate that leukemia can remodel BM stroma and vasculature, hijacking niche signaling to promote survival and drug resistance. However, translation of such findings to the human setting has been limited by the lack of humanized in vitro models that recapitulate key histopathological and functional features of human BM niches. Existing 2D culture systems fail to reproduce the spatial organization, mechanical properties and vascular networks that govern leukemia-niche interactions. Furthermore, current approaches often lack the ability to quantitatively resolve, in a compartment-specific manner, how distinct niche components and leukemia cells exchange signals, including soluble factors and extracellular vesicles, particularly under flow and chemotherapy exposure.

[0007] Summary of the Invention

[0008] The present invention provides a humanized engineered bone marrow (eBM) platform comprising at least two interacting 3D microenvironments that mimic (i) an endosteal-like niche and (ii)a vascular-like niche, optionally integrated within a microfluidic device configured for controlled perfusion and dynamic infusion of leukemia cells and / or drugs.

[0009] One aspect of the present invention regards the bone marrow niches, the endosteal-like niche, comprising a porous scaffold having bone-mimetic properties, optionally comprising collagen and hydroxyapatite nanoparticles (nanoHA) and / or other mineral components, while the vascular-like niche comprises a hydrogel supporting spontaneous formation of interconnected vascular networks from co-cultured stromal and endothelial cells, optionally a fibrin-collagen hydrogel.

[0010] In a further aspect, the invention provides a rapid vascularization protocol optimized for AML niche modeling, wherein robust interconnected vascular networks are achieved within a short maturation period (e. g., about three days) by controlling parameters such as endothelial-to-stromal ratios, cell origin (e. g., progenitor vs mature endothelial sources), cell density, and media / serum composition, thereby aligning system readiness Another aspect of the present invention regards a multiplex stable-isotope labeling workflow (e. g., 4-plex SILAC) wherein distinct cellular compartments are pre-labeled with different isotopic amino acids prior to assembly of the eBM and subsequent co-cultured under flow. In one embodiment, the invention provides a 4-plex SILAC multi-condition comparative proteomics pipeline integrated into the multi-compartment BM-on-chip system, enabling simultaneous profiling of:

[0011] 1 ) healthy BM niche state,

[0012] 2 ) AML diagnosis niche state,

[0013] 3) AML under-treatment niche state, and

[0014] 4 ) an internal reference state,

[0015] thereby mapping niche rewiring and drug resistance mechanisms beyond what is achievable by platforms integrating fewer conditions. The pipeline supports compartment-resolved recovery and analysis of (a) endosteal-attached niche cells, (b) vascular-located niche cells, (c) circulating AML blasts, and (d)secretome (including soluble factors and extracellular vesicles), followed by quantitative mass spectrometry to reconstruct directional signaling networks among compartments.

[0016] After interaction with AML blasts and / or chemotherapy, the platform enables compartment-resolved recovery of (a) endosteal-attached cells, (b) vascular-located cells, (c) circulating leukemia blasts, and (d) secretome, followed by quantitative mass spectrometry to reconstruct directional signaling networks and identify pathways associated with leukemia homing, niche remodeling, stress response, dormancy, survival and drug resistance.

[0017] The invention further regards methods and uses for drug testing and therapy guidance, including identifying niche-protective mechanisms and predicting or monitoring minimal residual disease and relapse risk, as well as kits comprising device components and labeling reagents to implement the methods.

[0018] Said uses comprise precision drug screening, therapy guidance and identification of biomarkers or pathway signatures associated with niche-mediated drug resistance, MRD and relapse risk.

[0019] Detailed description of the Invention

[0020] Definitions

[0021] " Endosteal-like niche" refers to a 3D microenvironment having mechanical and / or compositional properties resembling bone-adjacent marrow regions, optionally provided by a porous scaffold containing collagen and a mineral phase such as nanohydroxyapatite.

[0022] " Vascular-like niche" refers to a 3D hydrogel microenvironment supporting the assembly of interconnected vascular networks via co-culture of endothelial and stromal cells.

[0023] " Engineered bone marrow (eBM) " refers to a composite construct comprising at least two interacting niche regions, optionally with a circulation compartment for perfusion and cell / drug infusion." Multiplex isotope labeling" includes SILAC labeling using at least 3-plex or 4-plex isotope combinations for lysine / arginine labeling.

[0024] " Secretome" includes soluble factors and extracellular vesicles recovered from conditioned media.

[0025] Generation of Engineered niches

[0026] To generate vascular and endosteal niche microtissues, co-culture of distinct cell types within 3D hydrogels is performed to spontaneously obtain robust interconnected vascular networks, a key feature of native human BM. Importantly, to achieve these key specifications key technical features need to be met: i) a stiffer and highly porous hydrogel scaffold composed of Collagen I mixed with nanoHydroxyapatite (Collagen-nanoHA); patterned with ii) a softer Fibrin-Collagen I hydrogel. This hybrid approach allows to mimic the endosteal and vascular niches physical properties - in the same distinctive yet interacting system - while having a continuous vascularisation interconnecting both 3D microenvironments (Figures 1 and 2 ).

[0027] In one embodiment, primary human cell types from umbilical cord donors can be used (Figure 3).

[0028] In another embodiment vascular and endosteal niche co-cultures can be combined in a single niche-on-a-dish donut-patterned system. This patterned approach can functionally expand CD34+ HSCs fraction from the pool of Mononuclear Cells isolated from the umbilical cord blood, throughout 5 days of culture when compared to standard 2D suspension culture (Figure 4 ) reinforcing the hydrogel pivoting strategy.

[0029] Through application of this stabilized conceptual approach to the bioengineered human BM, a robust vascularization of niches is achieved, and this is a core feature of the marrow environment that is remarkably impacted during clinical leukaemia progression. Different embodiments of the present invention vary in terms of: i) Timing for decent formation of vascular networks ii) Stromal to Endothelial cell proportion iii) cell density iv) origin ofendothelial and stromal cell types and v) type of media and vi) amount of serum used in co-culture system (Figures 1 and 5 to 8 ). Vessel network performance can be assessed by vessel area, length, branching density, integrity / lacunarity, lumen formation and reproducibility metrics. The rapid maturation enables alignment with clinically relevant AML decision timeframes.

[0030] To achieve robust and reproducible vascularisation (with only 3 days of maturation - that is aligned with the experimental timeframe requirements of AML-niche interactions / SILAC proteomic studies in multiple experimental settings ), in the preferred embodiment of the present invention: a) the endosteal-like niche comprises a porous scaffold prepared from collagen (e.g., collagen I) combined with nano-hydroxyapatite, optionally freeze-dried to create an interconnected pore network; b) The scaffold may be seeded with stromal cells and / or osteoblast lineage cells; c) The vascular-like niche comprises a hydrogel (e.g., fibrin-collagen) containing endothelial cells and stromal cells, under conditions that promote spontaneous assembly of vascular networks within a maturation period (e. g., about 3 days).

[0031] Niche integration and microfluidic operation

[0032] The endosteal-like scaffold and vascular-like hydrogel are assembled into an integrated construct such that vascular structures form within or adjacent to the scaffold pores, generating a continuous vascularization across the microenvironments. The integrated construct may be cultured statically ("on-dish") or within a multi-chamber microfluidic device that enables controlled perfusion, maintaining a circulation compartment and permitting dynamic infusion of leukemia blasts and / or drugs. In one embodiment, commercially available chips µ-Slide I Luer 3D, iBIDI (with three interconnected chambers) are employed to co-culture developed niche microtissues under flow.

[0033] Using said microfluidic operation, the number of circulating AML blasts is stabilized in the presence of engineered hematopoieticniches despite their high proliferative index profile (Figure 9). Additionally, infused leukemic blasts tend to preferentially home into the eVascular niche - in detriment of eEndosteal regions -with localized settlement of leukemic colonies (Figure 10). Most strikingly, systemic infusion of leukemic blasts drives the depletion of eEndosteal niche vasculature while sparing the abundant networks formed within the eVascular niche counterpart (Figure 11 ). Surprisingly, eHaematopoietic BM niche constructs seem to protect Leukemic blasts from induction therapy (Figure 12 ).

[0034] The system enables functional readouts of blast survival, proliferation dynamics, niche protection, and stress responses consistent with emergence of drug-tolerant, stem-like or dormancy-associated phenotypes.

[0035] Leukemia interaction and induction therapy

[0036] Leukemia blasts (cell lines and / or patient-derived samples) may be introduced into the circulation compartment to model diagnosis state. After a defined interaction period, chemotherapy drugs (e. g., anthracyclines ) may be administered at defined concentrations to model induction therapy. The platform enables assessment of blast dynamics, preferential niche homing, niche remodeling (e. g., vascular depletion in selected regions), and blast survival in the presence of the engineered niche.

[0037] Multiplex proteomic mapping (e. g., 4-plex SILAC)

[0038] Distinct cell populations assigned to different compartments are pre-labeled with distinct stable-isotope amino acids prior to assembly. In one embodiment, at least a 4-plex SILAC technology is employed for comprehensive understanding of leukemic blasts heist over the basal niche signaling network in advanced organ-on-a-chip systems (Figure 13). In the said embodiment, distinct cell populations are assigned to the following niche compartments: ( 1 ) healthy niche state (no blasts, baseline), (2 ) AML diagnosis nichestate (blasts infusion), (3) AML under-treatment niche state (chemotherapy exposure), and (4 ) an internal reference state for normalization.

[0039] After co-culture and experimental perturbation (diagnosis-like blasts infusion and / or induction therapy), samples are recovered from each compartment:

[0040] (a) conditioned media and tubing contents to obtain secretome and circulating blasts;

[0041] (b) vascular-like hydrogel dissolution to obtain vascular-located niche cells; and

[0042] (c) scaffold recovery to obtain endosteal-attached cells.

[0043] Proteins are extracted and analyzed by quantitative mass spectrometry to identify compartment-origin proteins and infer signaling exchange among compartments, including changes induced by leukemia and by chemotherapy. The output enables identification of pathways supporting drug resistance, stress response, dormancylike states and MRD emergence.

[0044] As an example of this embodiment, induction treatment with 2xIC50 of doxorubicin triggers a massive stress response from both eEndosteal and eVascular BM niches which seem to signals — stem-like| phenotype towards AML blasts, potentially supporting their niche dormancy / survival (Figure 14 ).

[0045] Applications

[0046] The platform and methods can be used for (i) precision drug screening, (ii) mechanism-of-action studies, (iii) identification of biomarkers and pathways associated with relapse, (iv) evaluation of therapeutic combinations, and (v) patient stratification and therapy guidance, (vi) development and benchmarking of novel therapies aimed at disrupting leukemia-niche crosstalk.Examples

[0047] Example 1 — Assembly of integrated endosteal-like and vascular-like niches

[0048] A porous collagen-nanoHA scaffold is prepared and seeded with stromal and / or osteoblast lineage cells. A f ibrin-collagen hydrogel containing endothelial and stromal cells is introduced adjacent to or within a defined region of the scaffold to form a vascular-like niche. Constructs are matured under defined media and serum conditions for a period sufficient to form interconnected vascular networks.

[0049] Example 2 — Leukemia infusion and niche remodeling under flow Integrated constructs are placed in a microfluidic device comprising interconnected chambers. After maturation, AML blasts are infused into the circulation compartment and allowed to interact with the niches. Spatial localization of blasts and effects on niche vasculature are assessed.

[0050] Example 3 — 4-plex SILAC network reconstruction during diagnosis and induction therapy

[0051] Endosteal-associated cells, vascular niche cells and leukemia blasts are pre-labeled with distinct isotope combinations. After co-culture under flow, compartment-resolved recovery is performed, and proteins are quantified by MS. Differential network signatures are identified between (i) healthy niche, (ii) diagnosis-like blasts exposure, and (iii) induction-therapy exposure.

[0052] Brief description of the Figures

[0053] Figure 1 - Characterization of the engineered vascular-like and endosteal-like bone-marrow (BM) matrices. (A) Schematic illustration of BM-on-a-Dish 3D system composed by 3 interacting compartments: (i) Endosteal-like and (ii) Vascular-like patterned niches which can be (iii) integrated (or not) into microfluidic devices to add Circulating AML blasts, i) Vascular-like and endosteal-like microenvironments were individually characterized before being assembled into a combined ii) static BM-on-a-dish 3Dsystem, iii) Cross-sectional portions of the patterned BM-on-Dish engineered system can be integrated in microfluidic devices for creating advanced AML-on-Chip disease models. (B) Photographs and bright field / confocal microscopy imaging of (i) engineered Endosteal-like niche Collagen-nanoHA freeze-dried scaffolds, (ii) engineered Vascular-like niche (left and center-left columns). Image-based quantification of each matrix average pore / mesh size (center-right column) and viscoelastic properties, obtained from rheological analysis or nanoindentation measurements, of the f ibrin-collagen, collagen-nanoHA and / or Alginate-Collagen-nanoHA hydrogels is also provided (right column). Scale bar, 500 µm. Kruskal-Wallis with Turkey multiple comparison test, (P < 0.001 ).

[0054] Figure 2 - microscopy imaging of engineered microenvironments recapitulating the eVASCULAR, eENDOSTEAL bone marrow niches or a combination thereof upon 1 or 5 days of co-culture. eCONSTRUCT refers to the overall view of the entire hydrogel / scaffold (left) with a magnified view being displayed in the ZOOM-IN (right). (A and B) eVASCULAR NICHE (C and D ) eENDOSTEAL NICHE: 25 uL of media was aspirated from within the scaffold structure and replaced by another 25 uL of media with MSCs. Then the seeded cells were allowed to sediment within the scaffold structure - under a dry setting -in an incubator for 4 hours before adding additional media to the cell culture well. (E) elNTEGRATED NICHE: BM-MSCs pre-seeded Collagen-HA scaffolds were aspirated of residual media and subsequently filled 25 uL of eVASCULAR cell-embedded hydrogel. Only DAY 5 condition was performed for this condition. (F) eHAEMATOPOIETIC: 4mm core punctured rigid Collagen-HA scaffolds were pre-seeded with BM-MSCs as described (half of scaffold volume) were aspirated of residual media and subsequently the 4 mm diameter empty central core was filled with 25 uL of eVASCULAR cell-embedded hydrogel. Final construct is composed of external ring of rigid eENDOSTEAL with a central core of eVASCULAR. Staining legend: BLUE, DARI; RED, UEA I; GREEN, Actin. Effective Z thickness = 750 pm. Scale bar, 100 pm. Taken together, eVASCULAR alone the cells were able to drastically contract the matrix at DAY 5 and form somevascular networks, eENDOSTEAL the MSCs were homogenously distributed and spread (DAY 5) throughout the porous structure of the scaffold, elNTEGRATED the HUVECs of eVASCULAR Hydrogel were able to form a great degree of interconnected networks within the open pores of the eENDOSTEAL scaffold structure at DAY 5 and eHAEMATOPOIETIC the overall inner core / outer ring structure was maintained over time with moderate degree of interconnected vascular networks being observed at the inner eVASCULAR core.

[0055] Figure 3 - Isolation of multiple components of umbilical cord tissue & derivatives for recreating an engineered Bone Marrow (eBM) microenvironment. (A) Characterization of cord-blood MNCs & isolation of CD34+ cells by Fluorescence Activated Cell Sorting (FACS). (i) Schematic view of methodology used to isolate progenitor cells from umbilical cord blood, (ii) Total number of isolated mononuclear cells (MNCs) and corresponding cell viability per each cord blood unit, (iii) Summary of the subsets of CD34+ cells present in the isolated MNCs from 4 distinct UCB donors. The % of each subset seems to be donor dependent. Flow cytometry plot demonstrating the gating strategy for the sorting of CD34+ cells either from (iv) freshly isolated or (v) thawed UCB-derived MNCs. The process of thaw plus 48 hrs of in vitro culture seems to drastically decrease the % of CD34+ cells (vi) Photographs of sorted CD34+ cell populations at days 0, 3, 5 and 10 of 2D culture. (B) Characterization of donor-matched supportive cells isolated from umbilical cord tissues. Schematic representation of the isolation protocol of (i) WJ-MSCs, (ii) Artery or (iii) Vein Endothelial Cells from the umbilical cord tissue. Phase-contrast images illustrating the morphology of isolated (iv) WJMSCs, (v) Artery or (vi) Vein Endothelial cells after 12 days of in vitro culture, (vii) Percentages of WJ-MSCs expressing positive (CD105, CD73, CD90) and negative (CD34, CD14, CD45) mesenchymal stem / stromal cell markers as determined by flow cytometry, (viii) Percentages of endothelial and non-endothelial markers of isolated Arterial (HUAECs in red) or Vein (HUVECs in blue) endothelial cells, (ix) Percentage of closure in wound healing assays showingthe migration of HUAECs, HUVECs and OECs towards the center of the wound 9 h post-insert removal. Data is shown as the mean (N=3) + / -SEM. (x) Brightfield image of isolated endothelial cell forming tube-like structures onto Matrigel®-coated p-Slides. Automated quantification of angiogenic potential is displayed on top of image illustrating the number of Junctions (red), Segments (yellow), and Branches (green) formed within these tube-like structures. Image was obtained 16 hours after seeding onto Matrigel®-coated p-Slides. (xi) Quantification of tube formation from angiogenesis assay of HUAECs (red) and HUVECs (blue). Umbilical cord blood-derived outgrowth endothelial cells from a previous donor were used as reference control (black). Data represents the mean of 2 independent experiments (N=2 ) from cells isola Figure S3 - Assembly & characterization of the first preliminary version of bioengineered Bone Marrow Nicheon-a-Dish system. (A) Photography of the first version of assembled Niche-on-a-Dish illustrating the construction of the patterned 3D hydrogel system integrating both vascular and endosteal-like niches. Scale bar, 2 mm. (B) 3D reconstructions of the bioengineered Niche-on-a-Dish system The cells were pre-incubated with calcein (Live) and ethidium homodimer-1 (Dead) to access cell viability. White dotted line point the border between the endosteal and vascular niches. (C) Confocal image of WJ-MSCs covering the cell carrier used to mimic the shape and stiffness of trabecular pores of the endosteal niche. (D) Confocal image of the soft hydrogel environment used to mimic the vascular niche allowing cells to spread an interconnect with each other. Scale bar, 100 pm. (E) Estimated number of cells per cell carrier in endosteal niche. (F) Estimated number of cells in the vascular and endosteal niches. Distinct colours indicate distinct cell types. (G) Graph showing rheometric data of individual hydrogels niche components of the inner ( vascularlike ) and outer (endosteal) regions. Cell carrier stiffness embedded within endosteal niche is in the order of GPa. (H) Quantification of image data from (B) confocal images stained with calcein and ethidium, showing the percentages of live and dead cells in the total image or in the endosteal or vascular niches only. Sampleswith (and without) mitomycinC were quantified for cell viability at day 1. ( I ) Schematic experimental workflow for the flow cytometry experiment determining expansion of CD34+ progenitor subset of MNCs and functional ex vivo haematopoiesis in MNCs cultured (i) alone, in (ii) 2D or in (iii) 3D systems with cells from vascular or endosteal niches, or in (iv) both niches interfacing each other, the Niche-on-a-Dish engineered system for 5 days. Dual = patterned niches. (J) Percentages of total MNCs cell viability determined by 7-AAD staining expanded for 5 days in each of the expansion systems. (K) Total number of CD34+ progenitor cell subsets (total CD34+ cells, immature or mature progenitor cells) and corresponding frequencies within MNCs population upon 5 days of culture onto different biomimetic bone marrow expansion systems as analysed by flow cytometry. ted from 2 distinct UCB-donors.

[0056] Figure 4 - Assembly & characterization of the first preliminary version of bioengineered Bone Marrow Niche-on-a-Dish system. (A) Photography of the first version of assembled Niche-on-a-Dish illustrating the construction of the patterned 3D hydrogel system integrating both vascular and endosteal-like niches. Scale bar, 2 mm. (B) 3D reconstructions of the bioengineered Niche-on-a-Dish system The cells were pre-incubated with calcein (Live) and ethidium homodimer-1 (Dead) to access cell viability. White dotted line point the border between the endosteal and vascular niches. (C) Confocal image of WJ-MSCs covering the cell carrier used to mimic the shape and stiffness of trabecular pores of the endosteal niche. (D) Confocal image of the soft hydrogel environment used to mimic the vascular niche allowing cells to spread an interconnect with each other. Scale bar, 100 pm. (E) Estimated number of cells per cell carrier in endosteal niche. (F) Estimated number of cells in the vascular and endosteal niches. Distinct colours indicate distinct cell types. (G) Graph showing rheometric data of individual hydrogels niche components of the inner (vascular-like) and outer (endosteal) regions. Cell carrier stiffness embedded within endosteal niche is in the order of GPa. (H) Quantificationof image data from (B) confocal images stained with calcein and ethidium, showing the percentages of live and dead cells in the total image or in the endosteal or vascular niches only. Samples with (and without) mitomycin-C were quantified for cell viability at day 1. ( I ) Schematic experimental workflow for the flow cytometry experiment determining expansion of CD34+ progenitor subset of MNCs and functional ex vivo haematopoiesis in MNCs cultured (i) alone, in (ii) 2D or in (iii) 3D systems with cells from vascular or endosteal niches, or in (iv) both niches interfacing each other, the Niche-on-a-Dish engineered system for 5 days. Dual = patterned niches. (J) Percentages of total MNCs cell viability determined by 7-AAD staining expanded for 5 days in each of the expansion systems. (K) Total number of CD34+ progenitor cell subsets (total CD34+ cells, immature or mature progenitor cells) and corresponding frequencies within MNCs population upon 5 days of culture onto different biomimetic bone marrow expansion systems as analysed by flow cytometry.

[0057] Figure 5 - Interconnecting vascular networks spontaneously formed upon only 3 days of MSC / ECFCs co-culture in Fibrin-Collagen I hydrogels. (A) Experimental layout for fine tuning the spontaneous formation of interconnecting primitive vascular networks within the eVascular niche system for finding the optimal i) co-culture timing, ii) the endothelial to stromal cell ratio and iii) type of endothelial and stromal cell partnerships. Comprehensive analysis on the optimal network formation was comprehensively characterized based on image analysis of max proj ection images of vascular networks in each culture setting using AngioTool and or custom ImageJ macros to infer on the formation of vascular networks or track the evolution of cell number and cell type proportion over time, respectively. (B) Evolution of the formation of primitive vascular networks over 5 days of co-culture within eVascular hydrogel system. (i) Max proj ection images representing endothelial colony forming cells (red, UEA I lectin) positioning over time. Scale bar, 500 µm. Minimum time-frame required for the formation of interconnecting primitive vascular networks isobserved from day 3 onwards. Image based quantification of vascular network performance over 5 days of co-culture regarding (ii) % of vessel area, (iii) average vessel length, (iv) vessel branching density and (v) vessel integrity / lacunarity index, (vi) The number of cell nuclei per imaged z-section (number of BM-MSCs / ECFCs per lOx Field of View, left) and the corresponding coefficient of variation per FOV (right) was also quantified. (C) Cell proportion found at pre-formed vascular networks on day 3 of co-culture. (i) Enhanced Max Proj ection image illustrating the organization of both ECFCs (red, UEA I ) and BM-MSCs (exclusive green, Actin) within vascular networks found at day 3. Cell nuclei represented in blue. Scale bar, 100 pm. (ii) Relative cell proportion of Endothelial cells (ECs) and Mesenchymal Stem / Stromal Cells (MSCs) using automated FIJI image-based quantification tools. All results are expressed as the mean ± SEM. Ordinary one-way ANOVA, with Turkey multiple comparison test, or # (P < 0.05), (P < 0.01 ) and (P < 0. 001 ).

[0058] Figure 6 - Endothelial to stromal cell seeding proportion greatly impacts the performance and specifications of spontaneously formed interconnected vascular networks in eVascular niche system. (A) Multiple proportions of ECs to MSCs ( 0, 25, 50, 75, 95 or 100% ECs) were embedded in Fibrin-Col hydrogels at day 0 and co-cultured under eVascular niche conditions for 3 days prior analysis, (i) Max proj ection images of EC organization (UEA I, red) at day 3 using distinct proportions of ECs to MSCs at cell seeding. Scale bar, 500 µm. Image based quantification of vascular network performance over 3 days of co-culture regarding (ii) % of vessel area, (iii) average vessel length, (iv) vessel branching density and (v) vessel integrity / lacunarity index using AngioTool software. (B) Organization within pre-formed interconnecting vascular networks at day 3 upon distinct seeding cell proportions, (i) Enhanced Max proj ection inserts as defined in (A), illustrating the organization of MSCs (exclusive green, Actin) and ECs (Red, UEA I ) in pre-formed vascular networks throughout varying cell proportions at seeding. Scale bar, 200 pm. (ii) Fold change of thenumber of cell nuclei per field of view at day 3 relative to the corresponding experimental conditions imaged at day 0. Relative cell proportion of Endothelial cells (ECs) and Mesenchymal Stem / Stromal Cells (MSCs) using automated FIJI image-based quantification tools found at eVascular Niches (iii) upon seeding (day 0), (iv) upon co-culture (day 3) and the (v) relative fold change between them for the distinct experimental conditions, (vi) Orthogonal cross-sectional images representing x, y, z cell distribution of the formed vascular networks with 25, 50 or 75% of ECs relative to MSCs upon 3 days of coculture in eVascular Niche system. Observable luminal vascular structures in z-axis can be found in these multiple conditions. Scale bar, 50 pm. (vii) Quantification of the average vessel diameter formed in the distinct experimental conditions using FIJI software. All results are expressed as the mean ± SEM. Two-way ANOVA, with Turkey multiple comparison test. Multiple t tests (one per row) for EC to MSC fold change comparisons in (Bv). (P < 0.05), (P < 0.01 ), (P < 0.001 ) and (P < 0.0001 ).

[0059] Figure 7 - High density co-cultures with either ECFCs or HUVECs guarantees interconnected vascular networks of superior performance in eVascular niche system. (A) Progenitor ECFCs or (B) mature HUVECs were partnered with BM-MSCs at 1: 1 ratio in a low density ( 600 cell per pL) or in a high density (2400 cells per pL) and cocultured for 3 days within a eVascular niche system, (i) Max proj ection (ii) orthogonal cross-sectional images and (iii) 3D reconstruction representing x, y, z cell distribution of endothelial cell (red, UEA I lectin) and BM-MSCs (green, Actin) organization into vascular networks formed under each experimental setting. Scale bar, 500 pm or 50 pm. Image-based quantification of (iv) % of vessel area and (v) relative cell type proportion observed upon 3 days of co-culture for either conditions is shown in the right column of corresponding panel. (C) Image-based quantification of vascular network performance over 3 days of coculture regarding (i) total vessel length, (ii) vessel branching density, (iii) vessel integrity / lacunarity index and the (iv)average vessel diameter for each experimental condition. Results are expressed as the mean ± SEM. Ordinary one-way ANOVA, with Turkey multiple comparison test for all except for Ci plot. (Ci) Brown Forsythe and Welsh ANOVA, with Tamhane T2 test for due to unequal SD of the dataset. (P < 0.05), (P < 0.01 ), (P < 0.001 ) and (P < 0. 0001 ).

[0060] Figure 8 - The tissue origin of the stromal cell partner greatly impacts the performance of spontaneously formed vascular networks upon 5 days of co-culture in eVascular niche system. (A) Adult human Bone Marrow MSCs or (B) human umbilical cord Warthon' s Jelly-MSCs were partnered with mature HUVECs at 1: 1 ratio at a high density setting (2400 cells per pL) and co-cultured for 5 days within a eVascular niche system, (i) Max proj ection of vascular networks, (ii) enhanced image inserts and (iii) orthogonal cross-sectional images representing x, y, z cell distribution of endothelial cell (red, UEA I lectin) and BM-MSCs (green, Actin). Cell nuclei represented in blue. Collectively, images of formed vascular networks, show that BM-MSCs organize around the endothelial cell structures while WJ-MSCs seem more disconnected from these structures. Scale bar, 100 pm, 25 pm or 50 pm, respectively. (B) Image-based quantification of (i) relative cell type proportion and overall vascular network performance in terms of (ii) % of vessel area (iii) average vessel diameter, (iv) total vessel length, (v) vessel branching density and (vi) vessel integrity / lacunarity index observed upon 5 days of co-culture for either conditions in eVascular niche system. All results are expressed as the mean ± SEM. Two tailed, Unpaired t-tests for (B-i, ii, iv, v and vi datasets). Two tailed, MannWhitney test for (B-iii). (P < 0.05), (P < 0.01 ), (P < 0.001 ) and (P < 0.0001 ).

[0061] Figure 9 - The number of circulating AML blasts is stabilized in the presence of engineered hematopoietic niches despite their high proliferative index profile. (A) Schematic experimental design. (i) Two distinct subtypes of AML blasts (0CI-AML3 or MOLM-13) were culture either alone (AML, 2D TCPS), or infused in the eHematopoietic niches and cultured in static 3D half-well 96 wellplates (AML-on-DISH) or under 10 uL / min flow conditions in IBIDI Luer I uCHIPS (AML-on-CHIP). For both platforms, the engineered Haematopoietic niches were first allowed to self-assemble / mature for 3 days under — healthy|| conditions prior infusion (or not) of 50% AML blasts to the niche' s cell culture supernatant. AML blasts were then allowed to interact with the — healthy|| niches in designated platforms for another 3 days. Noteworthy, AML blast numbers to engineered niche cells components were maintained as similar as possible across distinct culture platforms. eHematopoietic BM niche system is composed of 3 interconnecting regions: a

[0001] high density cellular pre-cultured eVascular niche region (softer) patterned with an

[0002] adjacent bone-like eEndosteal region (stiffer) with cell culture nutrients and / or AML blasts being added / infused on the [3] eCirculation cell culture supernatant compartment. The AML 2D TCPS system designates the standard suspension monoculture of AML cell lines (no eNiche present). (ii) Photograph of the experimental system designated by AML-onCHIP where the eCirculation compartment is under constant flow imposed by a peristaltic pump-tube-uCHIP connection. Each uCHIP has 3 chambers with individual eHematopoietic niches (patterned eVascular plus eEndosteal niches). These systems were created to comprehensively analyze for the first time how the i) circulating blast dynamics, ii) preferential niche homing, iii) leukemic niche disruption ( vascularization / osteoblast depletion) and iv) basal niche / blasts signaling network is altered under distinct experimental settings. (B) Upon 3 days of AML blast culture in the distinct platforms (i) 2D TCPS monoculture, (ii) AML-on-DISH static 3D or (iii) AML-on-CHIP 3D under flow, the cell culture supernatant of each was thoroughly resuspended and transferred to a new well plate for automated image based cell counting of the number of circulating OCI-AML3 or MOLM-13 blasts. (C) Infused AML blasts were pre-labeled with cell tracker green to concomitantly estimate the number of cell divisions that circulating blasts undergone over a period of 3 days in the multiple culture platforms. (i) Representative Mean FluoresceIntensity (MFI ) histogram plots of cell tracker green labeled blasts recovered from circulation. Green, Cell Tracker stained blasts at day 0; Black, Unstained blasts auto fluorescence; Light gray, 2D TCPS monoculture; Light Blue, AML-on-DISH; Red, AML-on-CHIP. Estimated population divisions are illustrated in vertical light gray gates, (ii) Plot comparing the MFI values of circulating OCI-AML3 or MOLM-13 blasts immediately prior system infusion (day 0) or upon 3 days of co-culture in the designated system, (iii) Estimated number of cell divisions that circulating AML blasts undergone considering the 2x cell tracker signal dilution / MFI per cell division. (D) Cell cycle profile of retrieved circulating blasts in co-cultured under distinct platforms, (i) Representative cell cycle profile plots of each condition using univariate Watson Pragmatic algorithm to pinpoint G0 / G1 and G2 / M peaks, (ii) Plot of aggregated values of % of circulating blasts in G0 / G1, S and G2 / M phases of the cell cycle upon 3 days of culture. Cell cycle profile of AML blasts prior seeding (day 0, basal profile) is represented in light gray for comparison. All results are expressed as the mean ± SEM. Two-way ANOVA, with Turkey multiple comparison test. * (P < 0.05), ** (P < 0.01) and *** (P < 0.001 ).

[0062] Figure 10 - Infused leukemic blasts tend to preferentially home into the eVascular niche - in detriment of eEndosteal regions -with localized settlement of leukemic colonies. OCI-AML3 or MOLM-13 leukemic blasts were pre-labeled with cell tracker green and infused in the eCirculation compartment of (A) AML-on-DISH or (B) AML-onCHIP culture systems being allowed to interact with the engineered niches for 3 days. Max pro j ection / 3D reconstruction images of AML blasts' location (i) within the eVascular niche region, at the (ii) interface and (iii) at the endosteal scaffold area illustrating their preferable homing towards the first niche type. Dotted white line represents the interface between softer eVascular hydrogel and the stiffer eEndosteal scaffold environments. Scale bars, 100 pm or 50 pm. (iv) Quantification of the area / volume of engineered bone marrow construct occupied byeither eVascular-like or eEndosteal-like niche regions. (v) Relative percentage of leukemic blasts found within the engineered BM construct located either within the eVascular or eEndosteal niche regions, (vi) Preferential leukemic blast homing towards engineered niche regions normalized by the % of area occupied per each niche in the corresponding experimental system, (vii) Imagebased quantification of the relative positioning of niche-attached leukemic blasts found in the eVascular (left) or eEndosteal (right) niche regions illustrating that most blasts were located either directly on or in the near vicinity (5-10 pm) of a vascular network in AML-on-CHIP experiments. Results are expressed as the mean ± SEM. Two-tailed paired t-test. n / s, not significant.

[0063] Figure 11 - Systemic infusion of leukemic blasts drives the depletion of eEndosteal niche vasculature while sparing the abundant networks formed within the eVascular niche counterpart. Engineered Hematopoietic bone marrow (eBM) constructs were spontaneously assembled under optimized conditions over 3 days in (A) static 3D NICHE-on-DISH 96-well plate or in (B) uCHIP IBIDI Luer I chambers under continuous flow conditions. Then, prelabeled cell tracker green 0CI-AML3 or MOLM-13 blasts were infused in each system (comprising 50% of total healthy niche cells of the eBM construct to emulate the AML diagnostic scenario) and allowed to interact with the eNiches for another 3 days prior analyzing blasts impact on niche' s basal vascularization. The same volume in PBS was infused into the Healthy eBM setting for comparison, (i) Max proj ection images representing endothelial (red, UEA I lectin) cell distribution at day 6 of co-culture (Healthy) or upon 3 days of healthy maturation plus another 3 days of co-culture in the presence of infused OCI-AML3, or MOLM-13 leukemic blasts. Scale bar, 500 µm. Dotted white line represents the interface region between eEndosteal and eVascular niche regions. (ii) Higher magnification max proj ection image illustrating the presence of localized leukemic colonies (green, cell tracker) composed of few blasts retaining a high level of green intensity (slowly dividing) while most adjacent blasts carry minor levels of green fluorescenceintensity (highly proliferative). Noteworthy, these leukemic colonies seem to be predominantly found within the eVascular niche regions. Image-based quantification of vascular network performance - when no blasts (Healthy control), 50% of OCI-AML3 or MOLM-13 leukemic blasts were infused into the eBM system regarding (iii) % of vessel area (iv) average vessel length, (v) number of terminal-ended vessels and (iii) vessel integrity / lacunarity index. These observations seem to recapitulate some of the histopatological findings observed in patients' clinical bone marrow samples. (C) Apart from the erosion of eEndosteal niche vasculature we also observed that infused leukemic blasts tend to deplete the monolayer of mature femur osteoblasts either on 2D TCPS and when pre-seeded at the top and bottom pre-chambers of IBIDI Luer I uCHIPs (AML-on-CHIP). Results are expressed as the mean ± SEM. Ordinary one-way ANOVA, with Turkey multiple comparison test. * (P < 0.05).

[0064] Figure 12 - eHaematopoietic BM niche constructs protect Leukemic blasts from induction therapy. (A) The in vitro drug sensitivity / resistance of 0CI-AML3 and MOLM-13 leukemic blasts were screened against with 6 distinct AML therapy-related drugs (alone or in combination) at five different concentrations in 2D TCPS. Cell viability was simultaneously assessed with the (top) CellTiter-Glo luminescent cell viability assay and with the (bottom) Resazurin metabolic activity assay after 72 h. For each drug combination / cell line the corresponding IC50 value was determined. In vitro drug sensitivity is reproducible independently of the type of screening assay for 0CI-AML3 cells but some differences seem to be found for MOLM-13 blasts. (B) Next, we performed in vitro drug sensitivity / resistance of 0CI-AML3 and MOLM-13 leukemic blasts against 5 different concentrations of doxorubicin - either alone in standard 2D TCPS or upon AML blast infusion into the eBM niche constructs, (i) Cell viability was measured upon 72 hrs using CellTiter-Glo luminescent cell viability assay, (ii) Representative histogram of 0CI-AML3 andMOLM-13 circulating blasts cell viability - 72 hrs upon incubation with 100 nM of Doxorubicin in 2D TCPS or AML-on-DISH platforms -using high-throughput flow cytometry equipment. Altogether, data suggests that eBM niche-AML blasts interaction could favor drug resistance of the later compared to the standard 2D TCPS approach. (C) Impact of doxorubicin-based induction therapy on eBM niches vasculature, (i) Side-by-side max proj ection images of eEndosteal and eVascular niche vasculature (red, UEA I Lectin) when the healthy eBM niches (no AML blasts added) are allowed to maturate for 3 day plus 3 days in the absence of chemotherapy (green, No drug Control) or in the presence of 2xIC50 concentration of Doxorubicin (dark gray, 2xIC50 Doxo). eBM niche vasculature when the eBM niches are allowed to maturate for 3 day plus 16 hrs of interaction with infused (ii) OCI-AML3 or MOLM13 blasts (AML diagnosis state), plus another 3 days in the presence of 2xIC50 concentration of Doxorubicin ( Induction therapy state: dark gray, 2xIC50 Doxo). Scale bar, 100 pm. (iii) Image-based quantification of vascular network performance of leukemic eBM niches upon induction therapy regarding (top) % of vessel area within the niche and (bottom) branching density within each niche. (D) Max proj ection images of (left) OCI-AML3 and (right) MOLM-13 blasts location (Cell Tracker green) within eEndosteal / eVascular niche regions at AML diagnosis (blue) or upon 72 hrs of induction therapy (dark grey). Scale bar, 100 pm.

[0065] Figure 13 - 4-plex SILAC for the comprehensive understanding of leukemic blasts heist over the basal niche signaling network in advanced organ-on-a-chip systems. (A) Experimental approach of to monitor how AML blasts rewire the eBM niches' signaling networks to their advantage, (i) For that, the multiple cell components of eEndosteal ( femur Osteoblasts, K4 / R6), and eVascular (BM-MSCs and Endothelial cells, K8 / R10) niches and the infused circulating AML blasts (K6 / R4 ) were enriched in the designated stable isotope labeling of amino acids in cell culture (SILAC) prior eBM niche construct assembly. (ii) Upon 3 days of healthy eBM niche maturation, 50% of OCI-AML3 blasts (to the total of niche cells)were infused via entry port of the organ-on-chip device and allowed to interact with the eBM niches under flow in closed circulation for another 3 days. To comprehensively analyze the individual proteome / signaling of eEndosteal and eVascular niche cells and of circulating AML blasts at the end of co-culture the organ-on-chip system was open and immediately breakdown into multiple components to maximize the extracted information: All culture conditioned media was recovered from the chambers and tubing and centrifuged at 4°C. The collected supernatant has the soluble factors and extracellular vesicles used to intercellular communication (SECRETOME) while the centrifuged cell pellet contained the circulating 0CI-AML3 cells (CIRCULATING BLASTs). Simultaneously, the Fibrin-Collagen I matrix of the eBM niche constructs were dissolved in Nattokinase / Collagenase solution and centrifuged to pellet the eVascular niche cells (VASCULAR-NICHE LOCATED CELLs). Finally, the remaining eBM Collagen-nanoHA scaffolds with adhered femur Osteoblasts were transferred to an eppendorf, washed and lysed in RIPA Buffer at 4 °C (ENDOSTEAL -ATTACHED CELLs). All cell / scaffold pellets were washed 2x in ice cold PBS IX, freeze at -20°C and then processed for downstream 4-plex proteomic analysis. (B) Establishment of the healthy basal eBM niche signaling network, (i) Venn diagram of all tracked niche components illustrating the basal proportion of total aggregated proteins originating from each compartment upon 6 days of coculture, (ii) Venn diagrams demonstrating that several proteins produced by the eVascular niche cells are found in eEndosteal-attached niche cells and vice-versa suggesting an ongoing signaling network between these 2 compartments. Interestingly, few soluble / EVs protein can be found in the SECRETOME. In gray are the total number of ID human proteins (light SILAC KO / RO, normal protein turnover during unlabeled cell culture time) while in red / brown are the labeled proteins that can be backtracked to their origin. Noteworthy, is expected to a significant dilution of the SILAC labeling considering the extended co-culture time of niche cells (total of 6 days) and the high turn-over of AML blasts during the 3 days of AML interaction with the Healthy eBM niches. (C) Leukemic eBM niche signalingnetwork. (i) Venn diagram of all tracked niche components illustrating the relative contribution of each compartment to the total eBM niche proteome in an AML scenario, (ii) Venn diagrams demonstrating the leukemic signaling network between the AML Blasts and the eEndosteal and / or eVascular niche compartments and vice-versa. Interestingly, we found enrichment in the nicheoriginating proteins contributing to the overall SECRETOME in AML relative to the healthy counterpart. (D) Quantitative Venn Diagrams comparing the proteome changes in AML (blue) relative to the healthy counterpart (green) in (i) the Endosteal-attached cells, Vascular-located cells or in overall organ-on-a-chip systems' Secretome. (ii) Gene Ontology (GO) of the biological processes enriched / depleted in Osteoblasts, Endothelial cells (ECs) / BM-MSCs or stimulated / inhibited by soluble / EVs factors in systems' secretome upon healthy eBM niche cells interaction with AML blasts.

[0066] Figure 14 - Induction treatment with 2xIC50 of doxorubicin triggers a massive stress response from both eEndosteal and eVascular BM niches which seem to signals "stem-like" phenotype towards AML blasts, potentially supporting their niche dormancy / survival. (A) Experimental approach of MYLeukaemia to monitor how AML blasts rewire the eBM niches' signaling networks to survive induction therapy, (i) As before, the multiple cell components of eEndosteal ( femur Osteoblasts, K4 / R6), and eVascular (BM-MSCs and Endothelial cells, K8 / R10) niches and the infused circulating AML blasts (K6 / R4 ) were enriched in the designated stable isotope labeling of amino acids in cell culture (SILAC) prior eBM niche construct assembly, (ii) Upon 3 days of healthy eBM niche maturation, 50% of OCI-AML3 blasts (to the total of niche cells) were infused via entry port of the organ-on-chip device and allowed to interact with the eBM niches under flow in closed circulation for 12-16 hrs prior adding 2xIC50 of doxorubicin to the system inlet. The system was reconnected and cultured for another 3 days. As before, niche components were breakdown for a more comprehensive SILAC proteomic analysis. (B) Circulating AML blasts proteome / signaling network.(i) Venn diagram of all tracked niche components illustrating the relative contribution of each niche compartment to the circulating AML blast proteome at diagnosis and during induction therapy (2xIC50). Interestingly, we found a drastic enrichment in the niche-originating proteins in the Blasts proteome during induction therapy relative to diagnostic AML state counterpart. (ii) Quantitative Venn Diagrams comparing the proteome changes in AML blasts of proteins originating from their own AML blasts, eEndosteal or eVascular niche cells during induction therapy (dark grey) relative to the diagnostic AML counterpart (blue). (iii) Gene Ontology (GO) of the biological pathways promoted during induction by therapy-triggered blast-derived proteins, eEndosteal-derived or eVascular-derived niche proteins found in circulating / surviving AML blasts proteome relative to the AML diagnostic counterparts. (C) AML supportive niche proteome / signaling network. (i) Quantitative Venn Diagrams comparing the proteome changes during induction therapy (dark gray) relative to the diagnostic AML counterpart (blue) in the Endosteal-attached cells, Vascular-located cells or in overall organ-on-a-chip systems' Secretome. (ii) Gene Ontology (GO) of the biological processes enriched / depleted in Osteoblasts, Endothelial cells (ECs) / BM-MSCs or stimulated / inhibited by soluble / EVs factors in systems' secretome upon AML induction therapy.

[0067] References

[0068] H. R. Caires, Ó. Castillo-Fernandez, N. Sima, M. V. Magalhaes, A. Benavent-Claro, N. Maso-Castro, W. Roobsoong, C. Fernandez-Becerra, A. Hernandez-Machado, H. A. Del Portillo, C. C. Barrias, Advancing organ-on-chip models with a sacrificial granular hydrogel strategy for enhanced permeability and biomimicry. Small Methods 9, e00652, https: / / doi. org / 10.1002 / smtd.202500652 (2025). First quartile journal (QI ) with IF: 9.1;

[0069] Lin T, Zhong H, Niu Q, Zhang R, Zhao M, Zhou X. Construction Strategies and Advances in Bone Marrow Microphysiological Systems. International Journal of Molecular Sciences. 27 ( 8 ): 3586.https: / / doi. org / 10. 3390 / ijms27083586 ( 2026 ); First quartile j ournal ( QI ) with I F: 4. 9; (updated 2026 state of the art, independent review)

[0070] Lisbon, May 7th2026

Claims

CLAIMS1. A method for compartment-resolved mapping of leukemia-bone marrow niche signaling under diagnosis and / or chemotherapy conditions, comprising:(a) providing an engineered human bone marrow construct comprising at least (i) an endosteal-like niche and (ii) a vascular-like niche in fluidic communication with a circulation compartment;(b) pre-labeling at least three distinct cell populations assigned to different compartments with different stable-isotope amino acids for multiplex quantitative proteomics;(c) assembling and culturing said construct under conditions that form interconnected vascular networks within the vascular-like niche;(d) introducing leukemia blasts into the circulation compartment and allowing interaction with the engineered niches;(e) optionally introducing one or more therapeutic compounds into the system to model induction therapy;( f ) recovering, after a defined culture period, (i) endosteal-attached cells, (ii) vascular-located niche cells, (iii) circulating leukemia blasts, and (iv) secretome; and(g) performing quantitative mass spectrometry to determine compartment-origin proteins and infer signaling exchange between compartments.

2. The method of claim 1, wherein the multiplex quantitative proteomics comprises 4-plex SILAC labeling of distinct cell populations with different lysine and arginine isotope combinations.

3. The method of claim 1, wherein the endosteal-like niche comprises a porous scaffold comprising collagen and hydroxyapatite nanoparticles.

4. The method of claim 1, wherein the vascular-like niche comprises a f ibrin-collagen hydrogel containing endothelial cells andstromal cells at a defined ratio and cell density sufficient to form interconnected vascular networks within 2-5 days.

5. The method of claim 1, wherein the construct is integrated into a microfluidic device comprising at least three interconnected chambers configured for perfusion and sample recovery.

6. The method of claim 1, wherein recovering vascular-located niche cells comprises dissolving a vascular hydrogel matrix with an enzyme solution and collecting cells for proteomic analysis.

7. The method of claim 1, further comprising identifying, based on proteomic changes, pathways associated with leukemia survival, dormancy-like states, and / or drug resistance in the presence of the engineered niches.

8. An engineered human bone marrow microphysiological system comprising:(a) an endosteal-like niche region comprising a porous bonemimetic scaffold;(b) a vascular-like niche region comprising a hydrogel configured to support spontaneous formation of interconnected vascular networks;(c) a circulation compartment in fluidic communication with the niche regions; and(d) one or more ports configured for dynamic infusion of leukemia cells and / or therapeutic compounds and for recovery of compartment-resolved samples for multiplex proteomic analysis.

9. The system of claim 8, wherein the scaffold comprises collagen and nano-hydroxyapatite and the hydrogel comprises fibrin and collagen.

10. Use of the method of claim 1 or the system of claim 8 for precision drug screening, including identifying compounds orcombinations that reduce niche-mediated leukemia survival and / or drug resistance.

11. Use of the method of claim 1 or the system of claim 8 for identifying biomarkers and / or pathway signatures predictive of minimal residual disease and relapse risk.Lisbon, May 7th2026